SCRI

Vivek Subbiah, MD, Joins SCRI to Advance Early-Phase Clinical Research

Retrieved on: 
Thursday, May 11, 2023
Oncology, Health, Clinical Trials, Research, Pharmaceutical, Science, Journal of Clinical Oncology, US Food Sovereignty Alliance, MetroHealth, Drug development, Pediatrics, University, Therapy, MacLean Center for Clinical Medical Ethics, Nature Medicine, Ayas, European Medicines Agency, The New England Journal of Medicine, SCRI, ESMO, Cancer Discovery (journal), Clinical Cancer Research, Cancer, BRAF, Division, Case Western Reserve University, Multimedia, Monroe Dunaway Anderson, MD Anderson Cancer Center, Associate, Board certification, EMA, Sarah Cannon Research Institute, JAMA Oncology, Emil Frei, Journal, The Lancet, Pediatric Hematology and Oncology, Physician, Patient, Anderson, Internal medicine, Medicine, Translational research, Nature Reviews Clinical Oncology, Neoplasm, Principal, FDA, III, NIH, RET, Pharmaceutical industry, MD, Endocrinology

Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting clinical trials, is pleased to announce that Vivek Subbiah, MD, has joined the organization as Chief, Early-Phase Drug Development.

Key Points: 
  • Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting clinical trials, is pleased to announce that Vivek Subbiah, MD, has joined the organization as Chief, Early-Phase Drug Development.
  • “Vivek is a globally recognized key opinion leader for precision medicine and early-phase research,” said Howard A.
  • We are at the cusp of the next generation of personalized medicine that requires rapid and effective patient access to clinical trials,” said Dr. Subbiah.
  • Dr. Subbiah has authored over 350 peer-reviewed publications in several high-impact journals such as The New England Journal of Medicine, Nature Medicine, Journal of Clinical Oncology, JAMA Oncology, Cancer Discovery, Lancet Oncology, Nature Reviews Clinical Oncology, Lancet Diabetes and Endocrinology, and Clinical Cancer Research.

Mirati Therapeutics and Sarah Cannon Research Institute Announce Strategic, Community Site Focused Partnership to Increase Diversity in Oncology Clinical Studies

Retrieved on: 
Monday, May 8, 2023
Partnership, AACR, Drug development, Patient, SCRI, Mirati Therapeutics, Clinical trial, Cancer, American Association for Cancer Research, Human Development Innovation Fund, Research, Trial of the century, MD, Physician, SAN, Mirati, Inclusion, Health, Therapy, III, Sarah Cannon Research Institute, Pharmaceutical industry, Nursing

Ensuring equitable access to and participation in clinical studies requires improved awareness and targeted efforts to remove systemic barriers that may limit access to clinical studies for underrepresented patient groups.

Key Points: 
  • Ensuring equitable access to and participation in clinical studies requires improved awareness and targeted efforts to remove systemic barriers that may limit access to clinical studies for underrepresented patient groups.
  • As part of this partnership, Mirati and SCRI will implement practices and programs focused on removing obstacles to clinical study participation, including expanding physician and patient education and increasing access to community-based clinical trials.
  • Initiatives will be focused on reducing complexities associated with activating clinical trials thereby enabling a greater number of community practices to participate in research studies.
  • "The opportunity to partner with SCRI enables Mirati to advance diversity in our clinical studies, which is a key pillar of our Diversity, Equity, and Inclusion efforts.

LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope’s Ongoing Phase 1b Clinical Trial in Evaluating Lixte’s Lead Anti-Cancer Compound, LB-100, in Small Cell Lung Cancer

Retrieved on: 
Tuesday, April 4, 2023
Carcinoma, Therapy, PP2A, SCRI, Clinical trial, Glomus tumor, Lung cancer, Oncology, Research, Immunotherapy, Doctor of Philosophy, City, Patient, Sarah Cannon Research Institute, Pharmaceutical industry, Hope

PASADENA, CA, April 04, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) (“LIXTE” or the “Company”), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, announced that Sarah Cannon Research Institute (SCRI) ) at Tennessee Oncology in Nashville, Tennessee, is joining an ongoing Phase 1b clinical trial initiated at City of Hope, one of the largest cancer research and treatment organizations in the United States, to assess the combination of LIXTE’s first-in-class protein phosphatase 2A (PP2A) inhibitor LB-100 with a standard regimen for previously untreated, extensive stage disease small cell lung cancer (ED-SCLC) (NCT04560972).

Key Points: 
  • City of Hope continues as the coordinating center for the trial with Ravi Salgia, M.D., PhD, as the principal investigator.
  • The SCRI component of the trial will be led by Melissa Johnson, M.D.
  • Salgia and Johnson are nationally recognized leaders in lung cancer research and care.
  • Dr. Salgia’s protocol adds Lixte’s lead compound, LB-100, to both chemotherapy and immunotherapy in a promising new approach to this disease.”

Mythic Therapeutics Announces First Subject Dosed in Phase 1 KisMET-01 Clinical Trial of cMET-Targeting Antibody-Drug Conjugate (ADC) MYTX-011 for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

Retrieved on: 
Tuesday, April 4, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, SCRI, Clinical trial, Lung cancer, Pharmacokinetics, Mythic, NSCLC, Cell, Doctor of Philosophy, MD, Patient, Cancer, MET, ADC, Spacecraft, Therapy, Safety, Sarah Cannon Research Institute, Pharmaceutical industry

MYTX-011 is a cMET-targeting ADC being investigated for the treatment of patients with locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC).

Key Points: 
  • MYTX-011 is a cMET-targeting ADC being investigated for the treatment of patients with locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC).
  • “Today’s announcement of our first subject dosed represents a significant step towards increasing the number of lung cancer patients eligible for treatment using ADCs, including those whose cancers express moderate cMET levels,” said Brian Fiske, PhD, Chief Scientific Officer and Co-Founder at Mythic Therapeutics.
  • Part 1 will assess the safety and tolerability of MYTX-011 and identify the dose(s) to be studied in Part 2.
  • The first patient was dosed at Sarah Cannon Research Institute (SCRI) at Tennessee Oncology in Nashville, Tennessee, under the care of Melissa Johnson, MD, Director, Lung Cancer Research, SCRI.

PKF O'Connor Davies Releases 2023 Long Island Economic Survey Results

Retrieved on: 
Friday, January 27, 2023
Siena College Research Institute, SCRI, Hauppauge, PKF, Growth

NEW YORK, Jan. 27, 2023 /PRNewswire-PRWeb/ -- PKF O'Connor Davies, one of the nation's largest accounting, tax and advisory practices, today announced the results of its Long Island Economic Survey – Outlook 2023. Published since 1995, the Long Island Economic Survey provides a snapshot of Long Island's business landscape through the lens of the region's business leaders. The study reflects the economic challenges and opportunities currently impacting the business community, as well as those that leaders believe will arise in the coming year. Of note, respondents indicated the least amount of confidence in the Long Island economy since the inception of the Long Island Economic Survey, emphasizing the tumult they faced in 2022.

Key Points: 
  • NEW YORK, Jan. 27, 2023 /PRNewswire-PRWeb/ -- PKF O'Connor Davies, one of the nation's largest accounting, tax and advisory practices, today announced the results of its Long Island Economic Survey – Outlook 2023.
  • Published since 1995, the Long Island Economic Survey provides a snapshot of Long Island's business landscape through the lens of the region's business leaders.
  • Of note, respondents indicated the least amount of confidence in the Long Island economy since the inception of the Long Island Economic Survey, emphasizing the tumult they faced in 2022.
  • The Long Island Economic Survey – Outlook 2023 was unveiled at a launch event on January 24, 2023, at the Crest Hollow Country Club.

2seventy bio Provides Company Outlook for 2023

Retrieved on: 
Monday, January 9, 2023
Oncology, Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, JW, MAGE, Therapy, Architecture, AML, MUC16, SCRI, Cancer, Multiple myeloma, Acute myeloid leukemia, Abstract (summary), Regeneron Pharmaceuticals, Cost sharing, ASH, CAR, Growth, Progression-free survival, Acceleration, TCR, Patient, Engineering, Investigational New Drug, Drug discovery, Science, BMS, EBMT, Antibody, European, BCMA, Commercial, CBLB, Biologics license application, Pharmaceutical industry, Fine chemical, Bank, Idecabtagene vicleucel

2seventy bio, Inc. (Nasdaq: TSVT) announced today key corporate milestones and financial outlook for 2023.

Key Points: 
  • 2seventy bio, Inc. (Nasdaq: TSVT) announced today key corporate milestones and financial outlook for 2023.
  • As previously stated, 2seventy bio anticipates reaching the upper end of $250-$300M for topline U.S. revenue in 2022.
  • With this growth, 2seventy bio expects Abecma to generate $200-300M in operating income for 2seventy bio in the 2024-25 period.
  • Patient enrollment in CRC-403 continues at the second dose level, and 2seventy bio anticipates sharing a data update in 2023.

Sarah Cannon Research Institute to Present Latest Research Insights at the 2022 ASH Annual Meeting & Exposition

Retrieved on: 
Friday, December 9, 2022
Oncology, Health, Clinical Trials, Research, Pharmaceutical, Science, Exposition, Physician, Lymphatic system, Network, Chimeric antigen receptor T cell, Trial of the century, Sarah Cannon Research Institute, Health, Patient, Science, Cancer, Research, McKesson Corporation, GPRC5D, FDA, Drug development, CST, SCRI, Acute leukemia, The Network, Clinical trial, Relapse, Education, Cristian Berdeja, Blood, Pharmaceutical industry, Medicine, MD

Investigators highlighting research at this years ASH Annual Meeting & Exposition represent studies being conducted across SCRI, Sarah Cannon Transplant & Cellular Therapy Network, US Oncology Research, as well as partners from McKessons The US Oncology Network and Ontada.

Key Points: 
  • Investigators highlighting research at this years ASH Annual Meeting & Exposition represent studies being conducted across SCRI, Sarah Cannon Transplant & Cellular Therapy Network, US Oncology Research, as well as partners from McKessons The US Oncology Network and Ontada.
  • Sarah Cannon Research Institute (SCRI) is one of the worlds leading oncology research organizations conducting community-based clinical trials.
  • In 2022, SCRI formed a joint venture with US Oncology Research to enhance clinical trial access and availability across the country.
  • Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development.

NEW RESEARCH: Governments Can Support Better Access, More Efficient Healthcare Through Promotion of Self-Care

Retrieved on: 
Wednesday, October 19, 2022
Adoption, Population, Global, Research, WHO, Journal of Integrative Medicine, World, SCRI, Industry, Health, Department of Health and Social Care, Department, United Arab Emirates, GLOBE, United Kingdom, Healthcare, Pharmaceutical industry, Health insurance, Index

To support this, there needs to be a global compact on self-care at the international level, this will provide a frame for national-level policymakers to operate within."

Key Points: 
  • To support this, there needs to be a global compact on self-care at the international level, this will provide a frame for national-level policymakers to operate within."
  • Manoj Raghunandanan, Chair Elect at the Global Self-Care Federation said, "Self-care is a simple concept but it is not easy.
  • It takes a concerted effort by governments, healthcare professionals, academia, industry, and ultimately, the population at large.
  • But the potential rewards are high: better patient outcomes, more efficient healthcare systems and improved access to care."

Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer

Retrieved on: 
Wednesday, October 12, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, News, U.S. Securities and Exchange Commission, Sarah Cannon Research Institute, Therapy, Risk, Assistant, EGFR, MCRPC, Patient, TCE, Cytokine release syndrome, PSMA, Research, Tissue, Security (finance), Nasdaq, Cluster, Cancer, Immune system, SCRI, Pharmacokinetics, CEO, Adult, Safety, Prostate cancer, Trichloroethylene, CD28, Toxicity, Clinical trial, PD-L1, Half-life, Human, Hematological Cancer Research Investment and Education Act, Vaccine, Medical imaging, Pharmaceutical industry

Importantly, JANX007 has the potential for tumor-selective T cell activation and tumor cell killing, said Wayne Godfrey, M.D., Chief Medical Officer at Janux.

Key Points: 
  • Importantly, JANX007 has the potential for tumor-selective T cell activation and tumor cell killing, said Wayne Godfrey, M.D., Chief Medical Officer at Janux.
  • We look forward to exploring the safety and activity of this approach with JANX007 in prostate cancer patients.
  • We believe these characteristics have the potential to allow JANX007 to overcome the limitations that have beset previous T cell engagers in prostate cancer.
  • The Phase 1 clinical trial is a multi-center, open-label dose escalation trial to evaluate ascending doses of JANX007 in patients with mCRPC.

Harbinger Health and Sarah Cannon Research Institute Launch Clinical Study to Validate and Advance Development of Harbinger’s Novel Early Cancer Detection Platform

Retrieved on: 
Wednesday, June 29, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Diagnosis, Flagship Pioneering, Patient, Cancer, LinkedIn, Sarah Cannon Research Institute, Biotechnology, CEO, Biology, Research, Health, Trial of the century, HCA, Intelligence, Population, Disease, HCA Healthcare, CRO, Society, Clinical trial, Neoplasm, FACP, SCRI, Drug development, Labs, Twitter, MD, Multimedia, Pharmaceutical industry, Medical imaging

Harbinger Health, a biotechnology company pioneering the detection of early cancer, and Sarah Cannon Research Institute (SCRI) announced today the initiation of a 10,000-participant clinical study designed to validate and further develop Harbingers novel platform technology for blood-based early cancer detection.

Key Points: 
  • Harbinger Health, a biotechnology company pioneering the detection of early cancer, and Sarah Cannon Research Institute (SCRI) announced today the initiation of a 10,000-participant clinical study designed to validate and further develop Harbingers novel platform technology for blood-based early cancer detection.
  • The study, which is expected to read out in stages through 2023, is designed to advance Harbingers product development strategy.
  • Harbinger Health is pioneering the detection of early cancer and enabling foundationally new approaches to cancer screening, diagnosis and management.
  • Sarah Cannon Research Institute (SCRI) is the research arm of HCA Healthcares Cancer Institute, Sarah Cannon.